Table 2. Baseline characteristics of patients with carbapenem resistant A.baumannii bacteremia, grouped by sequence types.
| Chracteristics | Grouped by sequence type | ||||||
|---|---|---|---|---|---|---|---|
| ST191 | ST447 | Total | |||||
| ST191(N = 59) | Non ST191(N = 39) | p-value | ST447(n = 4) | Non ST447(n = 94) | p-value | ||
| Age, years | 59.27±14.70 | 63.13±14.39 | 0.21 | 77.0±10.74 | 60.09±14.41 | 0.05 | 60.62±14.63 |
| Gender, male | 37(62.7) | 32(84.2) | 0.02 | 3(75.0) | 66(71.0) | 0.67 | 69(70.4) |
| Comorbidities | |||||||
| DM | 43(72.9) | 32(82.1) | 0.23 | 2(50.0) | 73(77.7) | 0.24 | 75(67.5) |
| COPD | 55(93.2) | 37(94.9) | 0.56 | 4(100.0) | 88(93.6) | 0.77 | 92(93.9) |
| CHF | 49(83.1) | 34(87.2) | 0.42 | 4(100.0) | 79(84.0) | 0.51 | 83(84.7) |
| HTN | 36(61.0) | 26(66.7) | 0.40 | 2(50.0) | 60(63.8) | 0.47 | 62(63.3) |
| CRF | 42(71.2) | 32(82.1) | 0.18 | 3(75.0) | 71(75.5) | 0.69 | 74(75.5) |
| Chronic liver disease | 52(88.1) | 37(94.8) | 0.24 | 4(100.0) | 85(90.4) | 0.60 | 89(90.8) |
| Malignancy | 35(59.3) | 22(56.4) | 0.56 | 2(50.0) | 55(58.5) | 0.67 | 57(58.2) |
| Immunosuppressed status | |||||||
| Transplantation | 7(11.9) | 8(21/1) | 0.18 | 0(0.0) | 15(16.1) | 0.50 | 15(15.3) |
| Steroid usea | 20(33.9) | 10(26.3) | 0.29 | 0(0.0) | 30(32.3) | 0.22 | 30(30.6) |
| Chemotherapy | 23(39.0) | 16(42.1) | 0.46 | 2(50.0) | 37(39.8) | 0.53 | 39(39.8) |
| APACHE II | 21.32±8.16 | 21.26±7.18 | 0.97 | 23.25±3.50 | 21.22±7.881 | 0.35 | 21.17±7.81 |
| Admission episode(≥ once) | 42(71.19) | 25(64.10) | 0.27 | 3(75.0) | 64(68.1) | 0.62 | 67(68.4) |
| Source of infection | |||||||
| Respiratory tract | 46(82.1) | 32(88.9) | 0.29 | 4(100.0) | 74(78.7) | 0.35 | 78(79.6) |
| Other | 13(22.0) | 7(17.9) | 0(0.0) | 20(21.3) | |||
| Time to bacteremia | 21(12–41) | 19(12–41) | 0.38 | 12(8.2–37) | 20.5(12–41) | 0.21 | 20.5(12–41) |
| Invasive procedure | |||||||
| Ventilator | 47(79.7) | 33(86.8) | 0.27 | 4(100.0) | 76(81.7) | 0.47 | 80(81.6) |
| CRRTx | 18(30.5) | 11(28.9) | 0.53 | 2(50.0) | 27(29.0) | 0.35 | 29(29.6) |
| C-line insertion | 52(88.1) | 35(92.1) | 0.40 | 4(100.0) | 83(89.2) | 0.64 | 87(88.8) |
| Operation | 21(35.6) | 8(21.1) | 0.09 | 0(0.0) | 29(31.2) | 0.24 | 29(29.6) |
| Hospital stay (days) | 32(20–57) | 27(17–71) | 0.77 | 17(17–41) | 30(19–64.2) | 0.04 | 30(19–64.2) |
| ICU stay (days) | 22(11–38) | 19(8–52) | 0.34 | 17(15.5–33.5) | 21(9.8–40.5) | 0.34 | 21(9.8–40.5) |
| Duration of antibiotics | 31(17–57) | 25(16–69) | 0.84 | 16.5(16–41) | 30.5(16–59.3) | 0.07 | 30.5(16–59.3) |
| Duration of susceptible antibiotics | 0(0–9) | 8(0–17) | 0.36 | 4.5(0.3–10.8) | 2(0–11.25) | 0.76 | 2(0–11) |
| Susceptible antibiotics useb | 4(6.8) | 7(18.4) | 0.08 | 1(25) | 10(10.8) | 0.39 | 11(11.2) |
| All cause 28 day mortality | 52(88.1) | 27(71.1) | 0.16 | 4(100.0) | 75(80.6) | 0.81 | 79(80.6) |
Data of sequence types only with statistical significance are shown. Data are expressed as the mean ± SD / median (Q1-Q3) or N (%). Abbreviation: DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; HTN, hypertension; CRF, chronic renal failure; APACHE, acute physiology and chronic health evaluation; CRRTx., continuous renal replacement therapy.
*signifies having statistical significance with p-value<0.05 when compared to groups of the rest.
a Steroid use defined by use of ≥20mg prednisolone for ≥2weeks.
b We consider antibiotics susceptible when phenotypically susceptible antibiotics were used for more than half of time after culture recovered.